Enliven Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -5.47%
- Market cap
- $3.56B
- 73.6M shares
- Filings
- 799
—
—
—Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−20.3% FY25 yoy
- $3.56B
- —
- —
- 4.1×
- -1.98%
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Research And Development
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $85,856,000 | reported | |
| FY 2024 | 2024-12-31 | $80,778,000 | reported | |
| FY 2023 | 2023-12-31 | $64,574,000 | reported | |
| FY 2022 | 2022-12-31 | $31,022,000 revised | reported | |
| FY 2021 | 2021-12-31 | $38,442,000 | reported | |
| FY 2020 | 2020-12-31 | $32,154,000 | reported | |
| FY 2019 | 2019-12-31 | $19,009,000 | reported |
Pharmaceutical preparations
Enliven Therapeutics, Inc. is the 66th largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
SLNSilence Therapeutics plc$559.0K98.7%15,851.9%$3.7BACADAcadia Pharmaceuticals Inc$1.1B11.9%36.5%$3.7BOGNOrganon & Co.$6.2B2.9%3.0%$3.7B
ELVNEnliven Therapeutics, Inc. (this company)———$3.6B
AMLXAmylyx Pharmaceuticals, Inc.$0.0100.0%—$3.5BVKTXViking Therapeutics, Inc.$0.0——$3.5BVRDNViridian Therapeutics, Inc.$70.8M23,359.9%483.6%$3.5BSUPNSupernus, Inc.$1.2B4.3%16.9%$3.4BLEGNLegend Biotech Corp$1.0B64.0%28.8%$3.4BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Enliven Therapeutics, Inc. · CIK 1672619 · Engraved from SEC EDGAR